Drug Abuse |
Hallucinogens; Methadone; Narcotics; PCP (Phencyclidine) |
Clinical Trial: Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to determine whether Integrated Cognitive Behavioral Therapy or Twelve Step Facilitation Therapy is most effective for treatment of dually diagnosed veterans with depressive and substance use disorders.
| Condition | Treatment or Intervention |
|---|---|
| Major Depressive Disorder Alcohol Abuse Cannabis Abuse Substance-Related Disorders | Behavior: Integrated Cognitive Behavioral Therapy Behavior: Twelve Step Facilitation Therapy |
MedlinePlus related topics: Alcoholism; Drug Abuse; Inhalant Abuse; Marijuana Abuse; Mental Health; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Integrated CBT for Substance Use and Depressive Disorders
Study start: October 2004; Expected completion: September 2008
Depression is the most frequent co-occuring mental health disorder among adults with substance use disorders, and such comorbidity is often associated with poorer treatment outcomes. Although there is an urgent need for effective treatments specific for dual-diagnosis adults, few studies have been conducted to address this need.
Comparison: This study will compare substance use and depression symptoms of individuals in two different psychotherapy groups: Integrated Cognitive Behavioral Therapy and Twelve Step Facilitation Therapy. Symptoms and substance use will be compared during the active treatment phase (24 weeks) and for one year following the end of the active treatment.
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Individuals diagnosed with one or more substance use disorders (alcohol, cannabis, and or stimulant abuse/dependence) and an independent co-occurring depressive disorder (major depression or dysthymia) will be included.
Exclusion Criteria:
- Individuals with substance induced mood disorders and individuals experiencing persistent psychotic symptoms.
- Those with life threatening or unstable medical illness, neurological disorders, or inability to read will be excluded.
- Individuals currently prescribed steroids, disulfiram, or long acting benzodiazepines will be excluded.
Location and Contact Information
California
VA San Diego Healthcare System, San Diego, California, 92161, United States; Recruiting
Sandra Brown, Ph.D., Principal Investigator
More Information
Record last reviewed: April 2005
Last Updated: April 15, 2005
Record first received: April 14, 2005
ClinicalTrials.gov Identifier: NCT00108407
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-05-03
Source: ClinicalTrials.gov
Cache Date: May 4, 2005

Not Signed In -


